Extracellular matrix cues as drivers of liver zonation: A framework for in vitro biomaterial design
Source abstract
Abstract
The liver's complex microenvironment and spatially zonated functions present major challenges for in vitro modeling, particularly in drug development and disease research. While oxygen and nutrient gradients have been used to create zonation, the potential of the surrounding biomaterial, i.e. the extracellular matrix (ECM), remains relatively underexplored. Recently, native ECM components and/or binding motifs, such as decellularized ECM (dECM) or arginine-glycine-aspartate (RGD) peptides, are increasingly integrated to improve in vitro hepatocyte functionality. However, the biological underpinning of ECM-cell interactions and resulting hepatocyte behavior are often poorly understood, which hampers to exploit the full potential of biomaterial-based strategies for relevant liver tissue modeling. Within this context, the spatial ECM characteristics within the Space of Disse are of critical importance. In this review, we therefore first outline how ECM-receptor interactions influence hepatocyte function and then review how biomaterial composition and mechanics steer zone-specific cell functionality. We propose six practical design principles to guide biomaterial engineering for future applications, including mechanical tuning, affinity-guided selection, zone-specific ligand selection, enhanced ligand diversity, binding site accessibility, and native molecular environment preservation. These strategies will not necessarily increase model complexity, but may support intentional biology-driven biomaterial design beyond conventional scaffold macro-engineering, and enhance the physiological relevance of 3D liver models without sacrificing scalability, simplicity, or reproducibility. STATEMENT OF SIGNIFICANCE: There is an urgent demand for in vitro liver models that accurately reflect human biology for drug testing, disease modeling, and regenerative medicine. Existing systems rarely capture the liver's complexity, while animal models face ethical and translational constraints. A crucial but largely neglected feature is liver zonation, the region-specific variation in hepatocyte function. While oxygen and nutrient gradients are known to influence zonation, the role of extracellular matrix (ECM) cues remains underexplored. This review integrates evidence from hepatology, ECM-receptor biology, and biomaterials to propose an evidence-based, zonation-aware design framework. By translating biological principles into actionable material guidelines, it offers researchers the tools to develop next-generation liver models that better predict human outcomes and accelerate progress across the whole field.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Liver physiology and pathology · Tissue Engineering and Regenerative Medicine · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. MAFLD criteria guide the subtyping of patients with fatty liver disease10.2147/RMHP.S285880 ↗
2. Chronic liver diseases must be reduced worldwide: it is time to act10.1016/S2214-109X(22)00047-X ↗
3. Burden of liver diseases in the world10.1016/j.jhep.2018.09.014 ↗
4. Global burden of liver disease: 2023 update10.1016/j.jhep.2023.03.017 ↗
5. Global burden of metabolic dysfunction-associated steatotic liver disease from 1990 to 2021 and the prediction for the next 10 years10.1016/j.pmedr.2025.103248 ↗
6. Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review10.1038/s41598-021-85708-2 ↗
7. A critical perspective on 3D liver models for drug metabolism and toxicology studies10.3389/fcell.2021.626805 ↗
8. Generation of proliferating human adult hepatocytes using optimized 3D culture conditions10.1038/s41598-020-80019-4 ↗
9. Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach?
10. Human disease models in drug development10.1038/s44222-023-00063-3 ↗
11. Limitations of animal studies for predicting toxicity in clinical trials: part 2: potential alternatives to the use of animals in preclinical trials
12. U.S. Food and Drug Administration, FDA announces plan to phase out animal testing requirement for monoclonal antibodies and other drugs, 2025. https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs. (Accessed 13 July 2025).
13. National Institutes of Health, NIH to Prioritize Human-Based Research Technologies. 2025. https://www.nih.gov/news-events/news-releases/nih-prioritize-human-based-research-technologies. (Accessed 13 July 2025).
14. 3D hepatic organoid-based advancements in liver tissue engineering10.3390/bioengineering8110185 ↗
15. Liver-on-a-chip models of fatty liver disease10.1002/hep.31106 ↗
16. The native liver as inspiration to create superior in vitro hepatic models10.1039/D2BM01646J ↗
17. Current advances on 3D-bioprinted liver tissue models
18. Human induced pluripotent stem cell–derived liver-on-a-chip for studying drug metabolism: the challenge of the cytochrome P450 family10.3389/fphar.2023.1223108 ↗
19. Three-dimensional cell Co-culture liver models and their applications in pharmaceutical research10.3390/ijms24076248 ↗
20. Metabolic patterning on a chip: towards in vitro liver zonation of primary rat and human hepatocytes10.1038/s41598-018-27179-6 ↗
21. 3D microperfusion of mesoscale human microphysiological liver models improves functionality and recapitulates hepatic zonation10.1016/j.actbio.2023.09.022 ↗
22. In vitro metabolic zonation through oxygen gradient on a chip10.1038/s41598-019-49412-6 ↗
23. The role of liver zonation in physiology, regeneration, and disease, Seminars in liver disease
24. Extracellular matrix and liver disease10.1089/ars.2013.5697 ↗
25. The extracellular matrix in hepatic regeneration10.1096/fasebj.9.14.7589981 ↗
26. Hepatocyte-matrix interactions10.1136/gut.35.6.729 ↗
27. The role of matrix stiffness in regulating cell behavior10.1002/hep.22193 ↗
28. Mimicking physiologically relevant hepatocyte zonation using immunomodulatory silk liver extracellular matrix scaffolds toward a bioartificial liver platform10.1021/acsami.1c00719 ↗
29. Extracellular matrix modulates the spatial hepatic features in hepatocyte-like cells derived from human embryonic stem cells10.1186/s13287-023-03542-x ↗
30. Immunomodulatory role of the extracellular matrix within the liver disease microenvironment10.3389/fimmu.2020.574276 ↗
31. Extracellular matrix requirements for gastrointestinal organoid cultures10.1016/j.biomaterials.2021.121020 ↗
32. Spatiotemporal metabolic liver zonation and consequences on pathophysiology
33. Liver zonation–revisiting old questions with new technologies10.3389/fphys.2021.732929 ↗
34. Microanatomy of the human liver—Exploring the hidden interfaces10.1002/hep.510300607 ↗
35. Spatial sorting enables comprehensive characterization of liver zonation10.1038/s42255-019-0109-9 ↗
36. Single-cell spatial reconstruction reveals global division of labour in the mammalian liver10.1038/nature21065 ↗
37. Spatial transcriptomics to define transcriptional patterns of zonation and structural components in the mouse liver10.1038/s41467-021-27354-w ↗
38. Liver zonation, revisited10.1002/hep.32408 ↗
39. Metabolic zonation of the liver: the oxygen gradient revisited10.1016/j.redox.2017.01.012 ↗
40. Liver extracellular matrix in health and disease
41. The alterations in the extracellular matrix composition guide the repair of damaged liver tissue10.1038/srep27398 ↗
42. Atlas of mildly and highly insoluble matrisome driving liver fibrosis
43. Hepatic extracellular matrix and its role in the regulation of liver phenotype
44. The hepatic extracellular matrix: I. Components and distribution in normal liver10.1007/BF01606425 ↗
45. Reid · 1992 · 1198
46. Nyström · 2021 · 134
47. Liver sinusoidal endothelial cells in hepatic fibrosis: opportunities for future strategies
48. Extracellular matrix remodeling in chronic liver disease10.1007/s43152-021-00030-3 ↗
49. The extracellular matrix in hepatocellular carcinoma: mechanisms and therapeutic vulnerability10.1016/j.xcrm.2023.101170 ↗
50. Getting in the zone: metabolite transport across liver zones10.1111/apha.14239 ↗
51. Spatial single-cell mass spectrometry defines zonation of the hepatocyte proteome10.1038/s41592-023-02007-6 ↗
52. Mass spectrometry imaging for spatially resolved multi-omics molecular mapping10.1038/s44303-024-00025-3 ↗
53. Recent developments in spatial proteomics with MALDI mass spectrometry imaging: a journey toward clinical adoption10.1080/14789450.2025.2537212 ↗
54. High-resolution imaging mass cytometry to map subcellular structures
55. A framework for ultra-low-input spatial tissue proteomics10.1016/j.cels.2023.10.003 ↗
56. Laser capture microdissection and native mass spectrometry for spatially-resolved analysis of intact protein assemblies in tissue10.1039/D3SC04933G ↗
57. Spatial metabolomics and its application in the liver10.1097/HEP.0000000000000341 ↗
58. Spatial metabolic gradients in the liver and small intestine
59. Dynamic metabolic zonation of the hepatic glucose metabolism is accomplished by sinusoidal plasma gradients of nutrients and hormones10.3389/fphys.2018.01786 ↗
60. Hepatic zonation of carbon and nitrogen fluxes derived from glutamine and ammonia transformations10.1186/1423-0127-17-1 ↗
61. Scale-dependent mechanical properties of native and decellularized liver tissue10.1007/s10237-012-0426-3 ↗
62. The nanomechanical signature of liver cancer tissues and its molecular origin10.1039/C5NR02192H ↗
63. Elastic modulus measurements of human liver and correlation with pathology10.1016/S0301-5629(02)00489-1 ↗
64. Advances in the clinical use of collagen as biomarker of liver fibrosis10.1080/14737159.2020.1814746 ↗
65. Mechanostructure and composition of highly reproducible decellularized liver matrices10.1016/j.actbio.2013.10.023 ↗
66. Photocrosslinkable liver extracellular matrix hydrogels for the generation of 3D liver microenvironment models10.1038/s41598-021-94990-z ↗
67. Cellulose nanofibril hydrogel promotes hepatic differentiation of human liver organoids
68. Mechano-modulatory synthetic niches for liver organoid derivation10.1038/s41467-020-17161-0 ↗
69. Characterizing the effects of heparin gel stiffness on function of primary hepatocytes10.1089/ten.tea.2012.0681 ↗
70. Bile canaliculi formation and biliary transport in 3D sandwich-cultured hepatocytes in dependence of the extracellular matrix composition10.1007/s00204-016-1758-z ↗
71. The biological functions and clinical applications of integrins in cancers10.3389/fphar.2020.579068 ↗
72. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance10.1016/j.ccell.2019.01.007 ↗
73. Integrin recognition motifs in the human collagens
74. The molecular interaction of collagen with cell receptors for biological function10.3390/polym14050876 ↗
75. Integrins α1β1 and α2β1: the Generalist collagen receptors
76. Integrin α2β1 as a negative regulator of the laminin receptors α6β1 and α6β410.1016/j.micron.2021.103106 ↗
77. Regulation of hemidesmosome dynamics and cell signaling by integrin α6β410.1242/jcs.259004 ↗
78. Integrins and epithelial cell polarity
79. Fibronectin-integrin interactions10.2741/A178 ↗
80. Collagen receptors, biochemistry of collagens
81. A structural prospective for collagen receptors such as DDR and their binding of the collagen fibril
82. The dystroglycan: nestled in an adhesome during embryonic development10.1016/j.ydbio.2014.07.006 ↗
83. Structural basis of laminin binding to the LARGE glycans on dystroglycan10.1038/nchembio.2146 ↗
84. Laminin G-like domains: dystroglycan-specific lectins10.1016/j.sbi.2018.11.007 ↗
85. Dystroglycan expression in hepatic stellate cells: role in liver fibrosis10.1097/01.LAB.0000024429.73158.DE ↗
86. The collagen family members as cell adhesion proteins10.1002/bies.20636 ↗
87. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin10.1083/jcb.116.3.817 ↗
88. CD44 is involved in liver regeneration through enhanced uptake of extracellular cystine10.1002/ctm2.873 ↗
89. CD44 promotes hepatocellular carcinoma progression via upregulation of YAP10.1186/s40164-021-00247-w ↗
90. The role of glypican-3 in hepatocellular carcinoma: insights into diagnosis and therapeutic potential10.1186/s40001-024-02073-2 ↗
91. Emerging role of syndecans in extracellular matrix remodeling in cancer10.1369/0022155420930112 ↗
92. The role of glypican-3 in regulating wnt, YAP, and hedgehog in liver cancer10.3389/fonc.2019.00708 ↗
93. Syndecan-1 promotes hepatocyte-like differentiation of hepatoma cells targeting Ets-1 and AP-110.3390/biom10101356 ↗
94. Role of galectins in the liver diseases: a systematic review and meta-analysis10.3389/fmed.2021.744518 ↗
95. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma10.1002/(SICI)1097-0215(19990517)81:4<519::AID-IJC3>3.0.CO;2-0 ↗
96. Galectins and liver diseases10.3390/ijms26020790 ↗
97. Overexpression of galectin-1 and galectin-3 in hepatocellular carcinoma10.1016/j.livres.2020.11.001 ↗
98. Structural mechanism of laminin recognition by integrin10.1038/s41467-021-24184-8 ↗
99. Integrins: bidirectional, allosteric signaling machines10.1016/S0092-8674(02)00971-6 ↗
100. Targeting integrin pathways: mechanisms and advances in therapy10.1038/s41392-022-01259-6 ↗